Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside at the H.C. Wainwright Cell Therapy Virtual Conference.
NKTX - Nkarta, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$9.00
DETAILS
HIGH:
$9.00
LOW:
$9.00
MEDIAN:
$9.00
CONSENSUS:
$9.00
UPSIDE:
145.23%
Stock News
The $13 Million Company Teaching the Immune System to Hunt Cancer
/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP)
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings with outpatient dosing to reduce patient burden Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical meeting in 2026 Cash balance of $266.7 million on March 31, 2026, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026.
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
Nkarta stock jumps after FDA backs protocol changes for ongoing NKX019 studies, enabling outpatient dosing and boosting study efficiency, patient access and commercial potential.
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on key changes to the ongoing Ntrust-1 and Ntrust-2 clinical trials. The protocol amendments are designed to alleviate the need for overnight stays and reduce the overall burden on patients, enabling outpatient administration of NKX019 – an investigational CAR-NK cell therapy – by community research centers and community rheumatologists.
Nkarta to Participate in Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the 25th Annual Needham Virtual Healthcare Conference.
Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of “Hold” by Analysts
Nkarta, Inc. (NASDAQ: NKTX - Get Free Report) has earned a consensus rating of "Hold" from the five brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the fourth quarter and year ended December 31, 2025. “2025 was a year of strategic importance for Nkarta as we onboarded a clinical team with deep autoimmune experience, right-sized our workforce to be a responsible steward of investor capital, and continued to advance our CAR-NK cell therapy platform through dose escalation in the clinic,” said Paul J. Hastings, Chief Executive Officer of Nkarta. “Thoughtfully leveraging our safety data, we are now dosing patients at 4 billion cells in a three-dose cycle for a total of 12 billion cells as we look to maximize the depth and durability of B-cell depletion and clinical response, positioning us to unlock the full potential of NKX019 for people living with autoimmune disease.”
Bolt Biotherapeutics (NASDAQ:BOLT) versus Nkarta (NASDAQ:NKTX) Head to Head Review
Nkarta (NASDAQ: NKTX - Get Free Report) and Bolt Biotherapeutics (NASDAQ: BOLT - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk. Profitability This table compares Nkarta and Bolt Biotherapeutics'
Nkarta to Participate in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences:
Price Targets
Nkarta price target lowered to $9 from $25 at Evercore ISI
$9.00
(was $2.68)
Evercore ISI
Nkarta Inc. (NKTX) PT Raised to $16 at Canaccord Genuity
$16.00
(was $9.61)
Bill Maughan
·
Canaccord Genuity
These Analysts Revise Their Forecasts On Nkarta After Q4 Results
$15.00
(was $12.98)
Gil Blum
·
Needham
Nkarta Inc. (NKTX) PT Lowered to $25 at Mizuho on deprioritization of NKX101
$25.00
(was $8.92)
Salim Syed
·
Mizuho Securities
Raymond James Downgrades Nkarta Inc. (NKTX) to Outperform
$16.00
(was $8.92)
Laura Prendergast
·
Raymond James
Raymond James Maintains Outperform on Nkarta, Raises Price Target to $32
$32.00
(was $18.72)
Raymond James
HC Wainwright & Co. Maintains Buy on Nkarta, Raises Price Target to $36
$36.00
(was $18.72)
H.C. Wainwright